Efficacy of Sintilimab Combined with TP Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer

WU Xiancheng; SUN Lingxia; LI Hongmiao

doi:10.14033/j.cnki.cfmr.2025.28.011

Abstract：Objective:To investigate the therapeutic effect of sintilimab combined with TP chemotherapy on advanced non-small cell lung cancer(NSCLC).Method:A total of 104 patients with advanced NSCLC who were treated in the hospital from January 2020 to October 2022 were enrolled in the study.All patients were randomly divided into two groups using a draw method,with 52 patients in each group.The control group was treated with cisplatin plus paclitaxel(TP chemotherapy),while the observation group received cisplatin plus paclitaxel chemotherapy combined with sintilimab.Each treatment cycle lasted 21 days,with a total of 4 cycles for both groups.Clinical efficacy,immune function,tumor markers,and pulmonary function were compared between the two groups before and after treatment.Quality of life was assessed using the FACT-L(Functional Assessment of Cancer Therapy-Lung)scale.Adverse reactions were recorded,and all patients were followed for 2 years to document overall survival(OS)and survival rates.Result:The overall effective rate in the observation group was higher than that in the control group.The observation group showed significant improvements in immune function,pulmonary function,and quality of life scores compared to the control group,with lower tumor marker levels,with statistically significant differences(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Follow-up results revealed that the observation group had a longer overall survival and higher survival rate than the control group.Conclusion:The application of sintilimab combined with TP chemotherapy in the treatment of advanced NSCLC improves patients'immune function,pulmonary function,and quality of life.